These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11560006)

  • 1. [Correction of metabolic disturbances in patients with cholestasis].
    Rodonezhskaia EV; Kharchenko NV
    Lik Sprava; 2001; (3):148-9. PubMed ID: 11560006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of cholestatic liver disease].
    Pleşa A
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.
    Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O
    Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 5. Flare-up of autoimmune hepatitis after delivery in a patient with primary biliary cirrhosis: postpartum overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis.
    Ohba K; Omagari K; Kusakari C; Kadokawa Y; Hayashida K; Takeshima F; Mizuta Y; Murata I; Nakanuma Y; Kohno S
    Dig Dis Sci; 2005 Jan; 50(1):201-6. PubMed ID: 15712661
    [No Abstract]   [Full Text] [Related]  

  • 6. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
    Stojakovic T; Putz-Bankuti C; Fauler G; Scharnagl H; Wagner M; Stadlbauer V; Gurakuqi G; Stauber RE; März W; Trauner M
    Hepatology; 2007 Sep; 46(3):776-84. PubMed ID: 17668874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we treat cholestatic liver disease with cholesterol synthesis inhibitors?
    Schmidt HH; Manns MP
    Am J Gastroenterol; 1996 Feb; 91(2):406-7. PubMed ID: 8607528
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
    Polzien F; Ramadori G
    J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [No complaints, but constantly elevated cholestatic serum liver tests].
    Kherbèche H
    Praxis (Bern 1994); 2011 Jul; 100(14):865-7. PubMed ID: 21732301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid therapy in children with cholestatic liver disease.
    Dinler G; Koçak N; Yüce A; Gürakan F; Ozen H
    Turk J Pediatr; 1999; 41(1):91-8. PubMed ID: 10770681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
    Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
    Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
    N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid therapy in hepatobiliary disease.
    Kowdley KV
    Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Primary biliary cirrhosis (PBC)].
    Rautiainen H
    Duodecim; 2012; 128(15):1550-9. PubMed ID: 22970606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of cholestatic liver disease and therapeutic approaches.
    Hirschfield GM; Heathcote EJ; Gershwin ME
    Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of primary biliary cirrhosis].
    Szalay F
    Orv Hetil; 2003 Sep; 144(36):1787-8. PubMed ID: 14579676
    [No Abstract]   [Full Text] [Related]  

  • 19. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B.
    Kadayifci A; Savas MC; Arslan S; Güllú IH
    J Clin Gastroenterol; 1997 Mar; 24(2):125-6. PubMed ID: 9077736
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of cholestasis and cholestatic disorders.
    Sanyal A
    Indian J Gastroenterol; 2001 Mar; 20 Suppl 1():C88-9. PubMed ID: 11293189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.